Craig Hofmeister

28PUBLICATIONS
97CO-AUTHORS
Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersNanomedicineCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Aug 27, 2026
Accuracy of Real-Time PK-Guided Melphalan Dosing in Achieving Target Exposure in Myeloma Patients Undergoing Autologous Transplant.

|Jan 07, 2026
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.

Noffar Bar, Thomas Martin, Craig C Hofmeister

|Dec 09, 2024
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS.

Ola Landgren, Ajai Chari, Yael C Cohen

|Oct 28, 2024
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.

Alberto Moreno, Kelly Manning, Maryam I Azeem

|Sep 13, 2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.

Nisha S Joseph, Jonathan L Kaufman, Vilas A Gupta

|Jul 07, 2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.

Laura F Sun, Kathryn T Maples, Kevin H Hall

Pageof 5

Frequent Collaborators

12 joint publications

Jonathan L Kaufman

9 joint publications

Madhav V Dhodapkar

8 joint publications

Ajay K Nooka

7 joint publications

Vilas A Gupta